Home Biosciences is a new breed of biotech, leveraging an asset-centric operating model, designed to maximize efficiency in Biotech creation and scale-up, inspired from US corporations venture-funded biotech models.
Home Biosciences works together with leading teams to build and grow sustainable businesses, by assembling the right expertise and structure. Each project Home Biosciences takes on is housed in a dedicated entity (SPV), fully financed by Home Biosciences and led by teams focused on the day-to-day execution of its projects with oversight from the Home Biosciences management team.
Home Biosciences uses a capital-efficient and agile model with one centralized executive team, multiple shots on goal – with four to five fully funded ventures – up to major value inflexion points.
Home Biosciences is backed by leading biotech investors, Redmile Group and Sofinnova Partners.
Identify – Build – Grow
We work with academics and scientists on ground-breaking projects addressing unmet medical needs
We bring together talented, highly skilled execution teams and leverage innovative R&D approaches to maximize project outcomes.
We accelerate the discovery and development path thanks to rigorous processes, while making sure the interests of all parties are aligned
Focus – Execute
We assemble dedicated project teams that are empowered and accountable for day-to-day execution
We oversee execution to ensure that projects move forward on time
We provide funding and operational support to allow full focus of the project teams
One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat diseases. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Insitut Curie.
Sequantrix leverages one of the world’s largest human multi-modal, single-cell datasets in the field of fibrotic diseases to discover and validate novel targets and develop anti-fibrotic drug candidates up to the clinical proof of concept. The Company regroups leading pioneers in fibrosis research, clinical care and computational science to address the large, unmet medical need for antifibrotic therapies.
More to come
David Schilansky – co-founder & CEO
David has more than 20 years of professional experience, mainly in the pharma and biotech industry. From 2011 to 2020, he co-headed DBV Technologies, transforming the company from a French research start-up to a unicorn about to launch a treatment of primary importance in the US. During this period, he led two IPOs on Euronext and Nasdaq, raising more than one billion US dollars in total. David began his career as an investment banker in M&A at Warburg Dillon Read. He also worked at Ipsen, from 2005 to 2011, where he held various roles in finance, including that of Group Chief Financial Officer, before moving to DBVT. David graduated from Paris Dauphine and Imperial College (London).
Dr. Magali Richard – co-founder & deputy-CEO
Magali has 15 years of experience in biotech, combining academia and industry. Magali graduated from Ecole Polytechnique and Ecole des Mines de Paris, and holds a PhD in Molecular Biology. From 2009 to 2011 she was a Scientist at Biomarin, pursuing in the rare diseases space and gaining biotech experience in the US. Subsequently, Magali spent 6 years at the Boston Consulting Group, member of the Healthcare practice within the Paris office, working with various large pharma, biotech companies and investors, notably around new value creation models for emerging technologies. She then joined the Executive Committee of DBV Technologies as Chief Strategy Officer between 2016 and 2019, in charge of continuing the transformation from a biotech R&D company into an integrated pharmaceutical company.
Dr. Nicolas Doulet – Head of Business Development
Nicolas has 15 years of experience in public-private partnerships in healthcare. From 2007 to 2014, he worked at France Biotech and then at Orphanet for the promotion of preclinical and clinical research in rare diseases. He then joined OTR3 as Business Development and Communication manager. Since 2014, he developed industrial partnerships at Imagine – Institut des Maladies Génétiques, a French University Hospital Institute dedicated to the study, diagnosis and treatment of rare genetic diseases. He led key negotiations with pharmaceutical and biotech companies, as well as with academic institutions, enabling the development of dozens of preclinical, clinical development and startup creations. Nicolas holds a PhD in biology from Paris 6 and an advanced master’s degree in biotech administration and management (Masternova-Neoma Reims).
Guillaume Hagège – Head of Strategy & Operations
Guillaume has 10 years of experience in pharma and biotech. From 2018 to 2022, Guillaume worked at DBV Technologies, where he was notably heading the corporate and scientific strategy and a member of the Executive Committee. Prior to that, he was Project Leader at the Boston Consulting Group, where he spent six years as core member of the Healthcare practice, working with various large pharma and biotech companies, global health organizations or investors. Guillaume holds a master’s in strategic management from HEC Paris and a MSc from both Imperial College London and ISAE Supaero.
Romain Letourneur – Head of Legal
Romain has a long-standing experience in the pharma and biotech industry. Prior to joining Home Biosciences, Romain was General Secretary & In-house Legal Counsel of DBV Technologies, a Nasdaq and Euronext listed company with successively FPI and domestic issuer status. Throughout his career, Romain has been involved in numerous growth transactions, including licensing agreements with academic centers, research and co-development partnerships as well as complex financing operations. He has also acquired rock-solid US and EU corporate law matters and compliance, General Data Protection Regulation and, more globally, healthcare industry regulations. Romain holds a master’s degree in law from the University of Rennes.
Nian Nian (Reine) Wang – Head of Finance & Administration
Reine has 13 years of professional experience in finance. After graduating from EM Lyon Business School, Reine began her career in Audit before moving to Transaction Advisory Services at E&Y for six years. From 2015 to 2022, Reine held consecutively the position of Chief Financial Officer in three European groups: Ferretti group, the world leader in luxury yachts (where she was also Secretary of the Board); Demos Group, a global provider of vocational training services; and Theodo Group, a digital solutions provider. Amongst her achievements, Reine successfully led the restructuring of Ferretti that has since become a profitable group and carried out several capital increase and fundraising transactions
David Schilansky, Chairman & CEO
Magali Richard, deputy CEO
Ming Fang, Managing Director, Redmile Group
Antoine Papiernik, Managing Partner, Sofinnova Partners
Maya Saïd, independent board member